Tatva Chintan Pharma Chem Ltd
Tatva Chintan Pharma Chem Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Expecting 20% to 25% growth in revenue for FY 2026 compared to FY 2025. FY '26 revenue growth guidance: ~25% compared to FY '25.
From Tatva Chintan Pharma Chem Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Expecting 20% to 25% growth in revenue for FY 2026 compared to FY 2025.
- SDA (Structure Directing Agents) segment revenues anticipated to grow with better margin realization, supported by near full plant capacity utilization.
- Electrolyte salts segment projected to contribute roughly 10% to the top line by FY 26-27, with significant volume growth (~200% growth mentioned).
- PASC (Pharma & Agro and Specialty Chemicals) segment gaining traction, expected to be a significant revenue contributor in FY 26 and beyond.
- Semiconductor segment starting commercialization with full-scale expected by 2029, showing promising long-term potential.
- Addressable market in SDA estimated at around 20% currently, with further volume increases planned.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Tatva Chintan Pharma Chem Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- FY '26 capex plan is about INR 110 crores.
- New greenfield facility planned at Jolva to support additional capex for agro intermediate production.
- Minor capex under consideration for modifications and automation in semiconductor chemical production to move from pilot to plant scale.
- Additional capex expected for expanding electrolyte segment capacity, especially for supercapacitor and hybrid vehicle batteries requiring ultra-dry/ultra-pure handling and closed systems.
- Potential further expansions and automation anticipated for semiconductor and electrolyte businesses as volumes grow.
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Tatva Chintan Pharma Chem Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has high confidence in order execution with clear visibility of orders till at least December 2025.
- Most of the orders are already on hand, ensuring no uncertainty regarding near-term order fulfillment.
- Bulk orders in the PASC (Phase Transfer Catalyst) segment are set to commence supplies from early 2026.
- New orders and approvals in the electrolyte segment, including batteries for hybrid vehicles, indicate growing demand and commercial traction.
- There is clear visibility of significant orders ramping up in Q2 and Q3 of FY '26.
2 more points management made on order book & pipeline
Tatva Chintan Pharma Chem Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹134 Cr, net profit ₹10 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Tatva Chintan Pharma Chem Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
Others in Chemicals & Petrochemicals this season
- Balaji Amines Ltd (Q1 FY26)
Q1FY26 consolidated revenue from operations: ₹367 crore, up 2% quarter-on-quarter from ₹361 crore in Q4FY25, but down 7% year-on-year from ₹393 crore in Q1FY25…
- Linde India Ltd (Q1 FY26)
Net Revenue for FY ended Mar’25 was INR 24,854 million, down 10.2% (–2,833 million) YoY from INR 27,687 million. Key concall takeaways from Linde India Ltd's…
- Vidhi Specialty Food Ingredients Ltd (Q1 FY26)
87.9 Crores . Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- Chemcon Speciality Chemicals Ltd (Q1 FY26)
Q1 FY26 revenue from operations: ₹53.5 Cr, up 18% YoY from ₹45.5 Cr in Q1 FY25 (Page 7 & 6). Key concall takeaways from Chemcon Speciality Chemicals Ltd's Q1…
Frequently Asked Questions
What were Tatva Chintan Pharma Chem Ltd Q1 FY26 results?
Expecting 20% to 25% growth in revenue for FY 2026 compared to FY 2025. FY '26 revenue growth guidance: ~25% compared to FY '25.
What is Tatva Chintan Pharma Chem Ltd share price analysis?
Tatva Chintan Pharma Chem Ltd currently shows a neutral. The stock trades at a P/E of 76.8 with a market cap of ₹4,025 Cr. Investors should review the full earnings analysis for detailed insights.
Is Tatva Chintan Pharma Chem Ltd planning capital expenditure?
FY '26 capex plan is about INR 110 crores.
Keep Tatva Chintan Pharma Chem Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.